Literature DB >> 26312642

ψ-Bufarenogin, a lead compound of anti-cancer drug.

Jin Ding1, Hongyang Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26312642      PMCID： PMC4614062          DOI： 10.1080/15384101.2015.1071139

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Purification of active bufadienolides from toad skin by preparative reversed-phase liquid chromatography coupled with hydrophilic interaction chromatography.

Authors:  Yanfang Liu; Jiatao Feng; Yuansheng Xiao; Zhimou Guo; Jing Zhang; Xingya Xue; Jin Ding; Xiuli Zhang; Xinmiao Liang
Journal:  J Sep Sci       Date:  2010-06       Impact factor: 3.645

Review 2.  Lessons from natural molecules.

Authors:  Jon Clardy; Christopher Walsh
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

3.  Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells.

Authors:  Fanghua Qi; Anyuan Li; Lin Zhao; Huanli Xu; Yoshinori Inagaki; Dongliang Wang; Xiaoyan Cui; Bo Gao; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  J Ethnopharmacol       Date:  2010-03-01       Impact factor: 4.360

Review 4.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Authors:  Vince D Cataldo; Don L Gibbons; Román Pérez-Soler; Alfonso Quintás-Cardama
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

Review 5.  The global burden of liver disease: the major impact of China.

Authors:  Fu-Sheng Wang; Jian-Gao Fan; Zheng Zhang; Bin Gao; Hong-Yang Wang
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

6.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

7.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
  7 in total
  1 in total

Review 1.  Novel Strategies for Solubility and Bioavailability Enhancement of Bufadienolides.

Authors:  Huili Shao; Bingqian Li; Huan Li; Lei Gao; Chao Zhang; Huagang Sheng; Liqiao Zhu
Journal:  Molecules       Date:  2021-12-22       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.